Blog

Lauren Brown: Another insightful article out of the AURORA collaboration

Photo taken from www.clinical-lung-cancer.com

May 10, 2024, 14:58

Lauren Brown: Another insightful article out of the AURORA collaboration

Lauren Brown, PhD Candidate at Westmead Institute for Medical Research, University of Sydney & Medical Oncology Fellow at Westmead and Blacktown Hospitals, made the following post on X:

“Another insightful article out of the AURORA collaboration. Patients with KRAS, or PDL1 ≥50% are more likely to complete 24-months of pembro for NSCLC. Patients with oligoprogression in the brain treated with RT can still have enduring responses.”

Read the article.
Source: Lauren Brown/X

AURORA collaboration Blacktown Hospital brain metastases cancer cancer treatment KRAS mutation Lauren Brown Medical Oncology Fellow Medical Research NSCLC oligoprogression OncoDaily Oncology PD-L1 pembrolizumab PhD Candidate radiotherapy Research University of Sydney Westmead Hospital Westmead Institute for Medical Research

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Special Coverage